| Oct 18 |
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit
|
| Oct 9 |
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation
|
| Oct 8 |
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
|
| Oct 8 |
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate
|
| Sep 5 |
Oragenics, Inc. Announces Closing of Public Offering
|
| Sep 4 |
Oragenics stock plummets on selling 8.1M shares at $0.55 in public offering
|
| Sep 4 |
Oragenics, Inc. Announces Pricing of Public Offering
|
| Aug 21 |
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
|
| Aug 16 |
Oragenics files to sell 2.4M shares of common stock
|
| Aug 16 |
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
|
